We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

4 hedge funds and large institutions have $98.9K invested in NeuroSense Therapeutics Warrant in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

441% more capital invested

Capital invested by funds: $18.3K → $98.9K (+$80.6K)

33% more funds holding

Funds holding: 3 → 4 (+1)

0.22% more ownership

Funds ownership: 1.78% → 2% (+0.22%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$12.1K

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$5.56K
2
CS
Clear Street
New York
-$25

NRSNW Hedge Fund Activity: Q1 2024 in Review

4 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2024, worth a combined $98.9K — up 441% from $18.3K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new NRSNW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $12.1K. The largest seller was Warberg Asset Management, cutting an estimated $5.56K.

  • 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2024, up from 3 in Q4 2023.
  • Funds reported $98.9K of NeuroSense Therapeutics Warrant stock for Q1 2024, up 441% quarter-over-quarter.
  • 1 fund opened new NeuroSense Therapeutics Warrant positions in Q1 2024 and 0 closed out, a net change of +1 holder.
  • The largest NeuroSense Therapeutics Warrant buyer in Q1 2024 was Citadel Advisors, an estimated $12.1K added.
  • The largest NeuroSense Therapeutics Warrant seller in Q1 2024 was Warberg Asset Management, an estimated $5.56K sold.

Based on aggregated 13F filings for Q1 2024.